What is Roth Capital’s Forecast for MBRX Q1 Earnings?

Moleculin Biotech, Inc. (NASDAQ:MBRX) – Investment analysts at Roth Capital issued their Q1 2025 earnings per share estimates for Moleculin Biotech in a research report issued to clients and investors on Thursday, November 14th. Roth Capital analyst J. Aschoff forecasts that the company will post earnings of ($1.26) per share for the quarter. The consensus estimate for Moleculin Biotech’s current full-year earnings is ($8.60) per share. Roth Capital also issued estimates for Moleculin Biotech’s Q2 2025 earnings at ($1.25) EPS, Q3 2025 earnings at ($1.25) EPS and Q4 2025 earnings at ($1.25) EPS.

MBRX has been the subject of several other reports. Maxim Group reduced their target price on Moleculin Biotech from $20.00 to $8.00 and set a “buy” rating for the company in a research report on Tuesday, November 12th. StockNews.com began coverage on Moleculin Biotech in a research report on Wednesday, November 13th. They set a “sell” rating for the company.

Moleculin Biotech Stock Performance

Shares of MBRX opened at $2.71 on Monday. The stock’s fifty day moving average price is $2.52 and its two-hundred day moving average price is $3.29. Moleculin Biotech has a 1 year low of $2.12 and a 1 year high of $15.75.

Institutional Trading of Moleculin Biotech

An institutional investor recently raised its position in Moleculin Biotech stock. Armistice Capital LLC raised its holdings in shares of Moleculin Biotech, Inc. (NASDAQ:MBRX) by 5.1% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 156,000 shares of the company’s stock after purchasing an additional 7,505 shares during the period. Armistice Capital LLC owned approximately 6.75% of Moleculin Biotech worth $549,000 at the end of the most recent quarter. Institutional investors own 15.52% of the company’s stock.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.